Anti-Mouse CD8 [Clone YTS-169] — Purified in vivo GOLD™ Functional Grade
Anti-Mouse CD8 [Clone YTS-169] — Purified in vivo GOLD™ Functional Grade
Product No.: C2442
Clone YTS-169 Target CD8 Formats AvailableView All Product Type Monoclonal Antibody Isotype Rat IgG2b κ Applications Depletion , FC , IHC FF , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen CBA mouse thymocytes Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829540 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this YTS-169 antibody for staining cells in flow cytometry is ≤ 0.2 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. WB The suggested concentration for this YTS-169 antibody for use in western blotting is 1-10 μg/ml. Additional Applications Reported In Literature ? IHC (Frozen) Depletion Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone YTS-169 recognizes mouse CD8. Background CD8 is made up of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8 is part of the Ig superfamily that expresses primarily as CD8a homodimers. CD8a is a 32-34 kD type I glycoprotein that can also form heterodimers with CD8b. CD8 is an antigen co-receptor on T cells that mediates efficient cell to cell interactions within the immune system. CD8 coupled with the T cell receptor on the T lymphocyte recognizes an antigen displayed by an antigen presenting cell (APC) in the context of class I MHC molecules. The CD8 co-receptor also plays a role in T cell signaling by interacting with Lck (lymphocyte-specific protein tyrosine kinase) which leads to the activation of transcription factors that affect the expression of certain genes. Antigen Distribution CD8 is expressed on blood lymphocytes, a subset of NK cells, and thymocytes. Persons with HIV exhibit increased levels of CD8+ lymphocytes.
PubMed Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone YTS-169 (often YTS 169.4) is most commonly used in vivo in mice to deplete CD8⁺ T cells, specifically by targeting the CD8α chain on cytotoxic T lymphocytes. This allows researchers to study the immune function and role of CD8⁺ T cells in various settings by transiently or selectively removing this lymphocyte population. Key in vivo applications include:
Additional details:
Summary Table: Common In Vivo Applications of YTS-169 in Mice
The antibody is not generally used for in vivo tracking, staining, or activation—its primary validated role is depletion of CD8⁺ T cells. Commonly used antibodies or proteins with YTS-169 in the literature include anti-CD4 antibodies (such as YTA1.3.2), other CD8-specific antibodies (including clone 2.43 and YTS 156), and various reagents conjugated for flow cytometry or immune cell depletion. Key combinations and usage contexts:
Summary table of commonly paired reagents:
These combinations are critical for dissecting T cell responses and for precise immunophenotyping in mouse immunology studies. Scientific Significance of Clone YTS-169The clone YTS-169 (also cited as YTS169.4) is a well-established rat monoclonal antibody that specifically recognizes mouse CD8α, a cell surface glycoprotein expressed primarily on cytotoxic T lymphocytes. Since its development, YTS-169 has become a cornerstone tool in immunology for detecting, characterizing, and depleting CD8+ T cells in mice, enabling researchers to dissect the role of these cells in immune responses, disease models, and immunotherapy. Key Findings and ApplicationsDepletion of CD8+ T Cells
Flow Cytometry and Cell Staining
Structural and Molecular Insights
Broader Impact in Scientific Literature
Summary Table: Key Features of YTS-169
ConclusionClone YTS-169 is a foundational reagent in mouse immunology, enabling precise identification, isolation, and depletion of CD8+ T cells. Its use has been pivotal in elucidating the roles of CD8+ T cells in immune memory, autoimmunity, and disease pathogenesis, and it remains a gold standard for flow cytometric analysis of murine CD8α. Dosing regimens of clone YTS-169 (YTS169.4) in mouse models typically range from 200–400 µg per mouse every 3–7 days administered intraperitoneally (i.p.) or intravenously (i.v.), but can vary depending on strain, experimental objective, and desired depletion duration. Key context and variations:
Summary table of typical approaches:
Researchers are advised to titrate for their own experimental systems and consult lot-specific datasheets for precise recommendations. In summary: Most laboratories start at 200–400 µg every 3–7 days i.p. or i.v. per adult mouse, but regimens can be modified for strain, disease context, and experimental endpoints. References & Citations1. Parnes, J. R. et al. (1989) Adv. Immunol. 44:265 2. Reinherz, E. L. et al. (1980) J. Immunol. 124:1301 3. Fischer, A. et al. (1983) Immunology 48:177 4. Merkenschlanger, M. et al. (1988) Eur. J. Immunol. 18:1653 5. Leukocyte Typing: 3rd Workshop: Code No. 567; 4th Workshop: Code No. N31 Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
C2068 | |
C120 | |
C119 | |
C2060 | |
C2061 | |
C2062 | |
C2064 | |
C2066 | |
C366 | |
C2442 | |
C312 | |
C2850 |
Formats Available
